arrow
M

Murilo Luz

department of urology
H指数:13
被引数:2,071

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis

联合应用局部止血剂与肾实质缝合术与单纯肾实质缝合术在部分肾切除术中的比较:系统评价与Meta分析

2026-08-210
OAAI
NeuroSAFE-guided robot-assisted radical prostatectomy versus standard RARP: systematic review and meta-analysis of comparative studies

神经SAFE指导的机器人辅助根治性前列腺切除术与标准RARP的比较研究:系统评价和Meta分析

2026-05-130
OA
MRI AND PSMA PET-GUIDED FOCAL ABLATION OF LOCALIZED PROSTATE CANCER USING PULSED ELECTRIC FIELD (PEF) THERAPY WITH GALVANIZE: A NOVEL NON-THERMAL IMAGE-GUIDED APPROACH

MRI和PSMA PET引导的局限性前列腺癌脉冲电场(PEF)疗法聚焦消融(GALVANIZE):一种新颖的非热成像引导方法

2026-05-010
PRE
IDENTIFYING HIGHER RISK PATIENTS FOR URINARY TRACT INFECTION AFTER SHOCK WAVE LITHOTRIPSY: A SECONDARY ANALYSIS OF THE INTERNATIONAL APPEAL TRIAL

识别冲击波碎石术后尿路感染的高风险患者:国际APPEAL试验的二次分析

2026-05-010
PRE
68Ga-PSMA-11 in Staging of Unfavorable Intermediate-and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study

^{68}Ga-PSMA-11在不利于中危和高危前列腺癌分期中减少非治愈性前列腺切除术的指征:一项前瞻性、多中心、IAEA研究

2026-01-012
PRE
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

DARolutamide观察性(DAROL)研究:非转移性去势抵抗性前列腺癌患者的预先设定第三次中期分析

2025-11-010
OA
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

恩扎卢替尼在生化复发性前列腺癌中改善了生存率

2025-10-011
PRE
A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial

一项多中心随机对照试验,评估抗菌药物预防措施以预防肾结石碎石术后的尿路感染:APPEAL试验

2025-09-250
OAAI
Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT–based nomogram

使用基于18F-DCFPyL PSMA-PET/CT的列线图预测前列腺癌的侧特异性前列腺外侵犯

2025-07-230
PRE
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer

雄激素受体通路抑制剂疗法用于晚期前列腺癌

2025-01-132
OA
Subcutaneous versus intravenous nivolumab for renal cell carcinoma

皮下注射与静脉注射纳武利尤单抗治疗肾细胞癌

2025-01-010
OAAI
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

从安慰剂到达鲁他胺的交叉对非转移性前列腺癌男性总生存期的影响: 来自ARAMIS随机3期研究的敏感性分析

2023-12-010
OA
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

恩扎鲁他胺改善生化复发性前列腺癌的预后

2023-10-1984
PRE
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial
2023-03-019
OA
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial (vol 83, pg 212, 2023)
2023-02-011
OA